Correlation of plasma osteoprotegerin (OPG) and receptor activator of the nuclear factor κB ligand (RANKL) levels with clinical risk factors in patients with advanced carotid atherosclerosis

Medical Science Monitor

Volumn 18, Issue 10, 2012, Pages

  Giaginis, Constantinos ^a,b   Papadopouli, Aikaterini ^a   Zira, Athina ^a   Katsargyris, Athanasios ^a   Klonaris, Christos ^a   Theocharis, Stamatios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF THE AEGEAN   (Greece)

Author keywords

Atherosclerosis; Carotid; Medical history; OPG; RANKL; Risk factors

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADULT; AGED; ANAMNESIS; ARTICLE; CAROTID ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC DIET; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERLIPIDEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RISK FACTOR; SMOKING; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 84867606835     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.883485     Document Type: Article

References (61)

1. Simonet WS, Lacey DL, Dunstan CR et al: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 1997; 89: 309-19
2. Yamaguchi K, Kinosaki M, Goto M et al: Characterization of structural domains of human Osteoclastogenesis inhibitory factor. J Biol Chem, 1998; 273: 5117-23
3. Collin-Osdoby P, Rothe L, Anderson F et al: Receptor activator of NFkB and osteoprotegerin expression by human microvascular endothelia cell, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem, 2001; 276: 20659-72
4. Lacey DL, Timms E, Tan HL et al: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 1998; 93: 165-76
5. Hofbauer L, Schoppet M: Clinical implications of the osteoprotegerin/ RANKL/RANK system for bone and vascular disease. JAMA, 2004; 292: 490-95
6. Kong YY, Yoshida H, Sarosi I et al: OPGL is a key regulator of osteoclas-togenesis, lymphocyte development and lymph-node organogenesis. Nature, 1999; 397: 315-23
7. Gilmore TD: Introduction to NFkB: players, pathways and perspectives. Oncogene, 2006; 25: 6680-84
8. Collin-Osdoby P: Regulation of vascular calcification by osteoclast regulatory factors RANK-L and osteoprotegerin. Circ Res, 2004; 95: 1046-57
9. Emery JG, McDonnell P, Burk MB et al: Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem, 1998; 273: 14363-67
10. Sato K, Niessner A, Kopecky SL et al: TRAIL-expressing T cells induceapoptosis of vascular smooth muscle cells in the atherosclerotic plaque. J Exp Med, 2006; 203: 239-50
11. Hansson GK: Inflammatory mechanisms in atherosclerosis. J Thromb Haemost, 2006; 1: 328-31
12. Bonora E: The metabolic syndrome and cardiovascular disease. Ann Med, 2006; 38: 64-80
13. Niessner A, Goronzy JJ, Weyand CM: Immune-mediated mechanisms in atherosclerosis: prevention and treatment of clinical manifestations. Curr Pharm Des, 2007; 13: 3701-10
14. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation, 2002; 105: 1135-43
15. Spagnoli LG, Bonnano E, Sangiorgi G, Mauriello A: Role of inflammation in atherosclerosis. J Nucl Med, 2007; 48: 1800-15
16. Mallika V, Goswami B, Rajappa M: Atherosclerosis pathophysiology and the role of novel risk factors: a clinicobiochemical perspective. Angiology, 2007; 58: 513-22
17. Kiel DP, Kauppila LI, Cupples LA et al: Bone loss and the progression of abdominal aortic calcification over a 25 year period: The Framingham Heart Study. Calcif Tissue Int, 2001; 68: 271-76
18. Schulz E, Arfai K, Liu X et al: Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab, 2004; 89: 4246-53
19. Dhore CR, Cleutjens JP, Lutgens E et al: Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol, 2001; 21: 1998-2003
20. Bucay N, Sarosi I, Dunstan CR et al: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev, 1998; 12: 1260-68
21. Min H, Morony S, Sarosi I et al: Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclast and prevents vascular calcification by blocking a process ressembling osteoclastogenesis. J Exp Med, 2000; 192: 463-74
22. Price PA, June HH, Buckley JR, Williamson MK: Osteoprotegerin inhibits vascular calcification by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol, 2001; 21: 1610-16
23. Bennett BJ, Scatena M, Kirk EA et al: Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in ApoE-/-mice. Arterioscler Thromb Vasc Biol, 2006; 26: 2117-24
24. Orita Y, Yamamoto H, Kohno N et al: Role of osteoprotegerin in arterial calcification: development of new animal model. Arterioscler Thromb Vasc Biol, 2007; 27: 2058-64
25. Morony S, Tintut Y Zhang Z et al: Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in Idlr(-/-) mice. Circulation, 2008; 117: 411-20
26. Nybo M, Rasmussen LM: The capability of plasma osteoprotegerin as apredictor of cardiovascular disease: a systematic review. Eur J Endocrinol, 2008; 159: 603-8
27. Papadopouli AE, Klonaris CN, Theocharis SE: Role of OPG/RANKL/ RANK axis on the vasculature. Histol Histopathol, 2008; 23: 497-506
28. Van Campenhout A, Golledge J: Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis, 2009; 204: 321-29
29. Venuraju SM, Yerramasu A, Corder R, Lahiri A: Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol, 2010; 55: 2049-61
30. Golledge J, McCann M, Mangan S et al: Osteoprotegerin and Osteopontin are expressed at high concentrations within carotid atherosclerosis. Stroke, 2004; 35: 1636-41
31. Schoppet M, Al-Fakhir N, Franke FE, Katz N, Barth PJ, Maisch B, et al. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Monckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab, 2004; 89: 4104-12
32. Kadoglou NP, Gerasimidis T, Golemati S et al: The relationship between serum levels of vascular calcification inhibitors and carotid plaque vulnerabiity. J Vasc Surg, 2008; 47: 55-62
33. Vik A, Mathiesen E, Noto A et al: Serum osteoprotegerin is inversely associated with carotid plaque echogenicity in humans. Atherosclerosis, 2007; 191: 128-34
34. Akinci B, Bemir T, Celtik A et al: Serum osteoprotegerin is associated with carotid intima media thickness in women with previous gestational dianetes. Diab Res Clin Pract, 2008; 82: 172-78
35. Liapis CD, Bell PR, Mikhailidis D et al: ESVS guidelines. Invasive treatment for carotid stenosis: indication, techniques. Eur J Vasc Endovasc Surg, 2009; 37: 1-19
36. Howard G, Prineas R, Moy C et al: Racial and geographic differences inawareness, treatment, and control of hypertension: the reasons for geographic and racial differences in stroke study. Stroke, 2006; 37: 1171-78
37. Smilde TD, van Veldhuisen DJ, Navis G et al: Drawbacks and prognostic value of formulas estimating renal function in patients with chronicheart failure and systolic dysfunction. Circulation, 2006; 114: 1572-80
38. Giaginis C, Zira A, Katsargyris A et al: Clinical implication of plasma neutrophil gelatinase-associated lipocalin (NGAL) concentrations in patients with advanced carotid atherosclerosis. Clin Chem Lab Med, 2010; 48: 1035-41
39. Castro R, Rivera I, Blom HJ et al: Homocysteine metabolism, hyperhomocysteinaemia and vascular disease. J Inherit Metab Dis, 2006; 29: 3-20
40. Vik A, Mathiesen EB, Johnsen SH et al: Serum osteoprotegerin, sRANKL and carotid plaque formation and growth in a general population the Tromsø study. J Thromb Haemost, 2010; 8: 898-905
41. Vik A, Mathiesen EB, Brox J et al: Relation between serum osteoprotegerin and carotid intima media thickness in a general population - the Tromsø Study. J Thromb Haemost, 2010; 8: 2133-39
42. Golledge J, Leicht AS, Growther RG et al: Determinants of endothelial function in a cohort of patients with peripheral artery disease. Cardiol, 2008; 111: 51-56
43. Moran C, McCann M, Karan M, Norman P: Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation, 2005; 111: 3119-25
44. Ziegler S, Kudlacek S, Luger A, Minar E: Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis, 2005; 182: 175-80
45. Jono S, Otsuki S, Higashikuni Y et al: Serum osteoprotegerin levels and long-term prognosis in subjects with stable coronary artery disease. J Thromb Haemost, 2010; 8: 1170-75
46. Schoppet M, Sattler AM, Schaefer JR et al: Increased osteoproteger- in serum levels in men with coronary artery disease. J Clin Endocrinol Metab, 2003; 88: 1024-28
47. Ren MY, Sui SJ, Zhang Y et al: Increased plasma osteoprotegerin levels are associated with the presence and severity of acute coronary syndrome. Acta Cardiol, 2008; 63: 615-22
48. Semb AG, Ueland T, Aukrust P et al: Osteoprotegerin and soluble receptor activator of nuclear factor-kappa B ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003. Arterioscler Thromb Vasc Biol, 2009; 29: 975-80
49. Abedin M, Omland T, Ueland T et al: Relation of osteoprotegerin to coronary calium and aortic plaque (from the Dallas Heart Study). Am J Cardiol, 2007; 99: 1886-89
50. Kiechl S, Schett G, Schwaiger J et al: Soluble receptor activator of nuclear factor-kappa B ligand and risk for cardiovascular disease. Circulation, 2007; 116: 385-91
51. Lieb W, Gona P, Larson MG et al: Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident CVD and mortality. Arterioscler Thromb Vasc Biol, 2010; 30: 1849-54
52. Sadowitz B, Maier KG, Gathan V: Basic science review: Statin therapy- part I: the pleiotropic effects of statins in cardiovascular disease. Vasc Endovascul Surg, 2010; 44: 241-51
53. Celinska-Lowenhoff M, Lowenhoff T, Undas A, Gluszko P: Effects of hypolipemic drugs on the osteoprotegerin-RANKL system in patients with coronary artery disease. Thromb Haemost, 2007; 97: 868-70
54. Nellemann B, Gormsen LC, Dollerup J et al: Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria. Diabetes Care, 2007; 30: 3122-24
55. Mori K, Jono S, Emoto M et al: Effects of pravastatin on serum osteoprotegerin levels in patients with hypercholesterolemia and type 2 diabetes. Angiology, 2010; 61: 86-91
56. Nezami N, Safa J, Eftekhar-Sadat AT et al: Lovastatin raises serum osteoprotegerin level in people with type 2 diabetic nephropathy. Clin Biochem, 2010; 43: 1294-99
57. Nitta K, Akiba T, Uchida K et al: Serum osteoprotegerin levels and the extent of vascular calcification in hemodialysis patients. Nephrol Dial Transplant, 2004; 19: 1886-89
58. Gonnelli S, Montagnani A, Caffarelli C et al: Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients with chronic hemodialysis. J Endocrinol Invest, 2005; 28: 534-39
59. Morena M, Dupuy AM, Jaussent I et al: A cutt-off value of plasma osteoprotegerin value may predict the presence of coronary artery calcification in chronic kidney disease patients. Nephr Dial Transplant, 2009; 24: 3389-97
60. Sato T, Tominaga Y Iwasaki Y et al: Osteoprotegerin levels before and after renal transplantation. Am J Kidney Dis, 2001; 28: S175-77 61.
61. Chan BY, Buckley KA, Durham BH et al: Effect of anticoagulants and store temperature on the stability of receptor activator for nuclear factor-kappa B ligand and osteoprotegerin in plasma and serum. Clin Chem, 2003; 49: 2083-85